Novan's interim CEO outlines future focus

Novan ’s (Nasdaq: NOVN) interim CEO Kelly Martin – who is also CEO of Novan shareholder Malin Life Sciences Holding – said on an investor call Wednesday morning that strengthening Novan’s balance sheet is the most important focus in the near-term. Cash has continued to be a primary concern for Mo rrisville-based Novan in recent months, and the company has been struggling to regain footing following mixed Phase 3 trial results for its acne product SB204 that sent its stock plummeting 75 percent. As…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news